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We refer to your recently published reportentitled N-terminal pro brain natriuretic pep-
tide in coronary artery disease [1]. Radwan et al.
describe NT-proBNP as a ‘valuable marker for
predicting prognosis and severity of coronary
artery disease in patients with acute coronary syn-
drome’ [1]. In fact, the clinical usefulness of NT-
proBNP has been widely discussed. Ranjith et al.
examine the usefulness of this biomarker and sug-
gest that NT-proBNP ‘should be included in the
risk assessment of ACS to provide guidance for
further therapeutic strategies’ [2]. Nevertheless,
conditions exist that might affect NT-proBNP
values, such as underlying renal problems and
anemia [3]. In a recent report, the limitation of
NT-proBNP is cited for ‘very old people with
limiting dyspnea’ [4]. In the report by Radwan
et al. further analysis to analyze the effect ofpossible underlying comorbidities should be
implemented. Further investigation to compare
NT-proBNP with other clinical parameters as well
as cost effectiveness analysis could also be the
basis of future studies.
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